Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.

Mycoses - 1 Nov 2012

Racil Zdenek, Winterova Jana, Kouba Michal, Zak Pavel, Malaskova Ludmila, Buresova Lucie, Toskova Martina, Lengerova Martina, Kocmanova Iva, Weinbergerova Barbora, Timilsina Shira, Rolencova Monika, Cetkovsky Petr, Mayer Jiri

Abstract excerpt

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematological patients (median 3 samples/patient; range 1-27) receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA) (46.3% of samples),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aspergillosis

Share to Cytochrome P-450 CYP2C19

Share to Drug Monitoring

Share to Hematologic Diseases

Share to Triazoles

Share to Voriconazole

Source

Identifiers

PMID: 22429709
DOI: 10.1111/j.1439-0507.2012.02186.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.PMID 22429709Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.Semantic proximity Read ↗

Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of VoriconazoleSemantic proximity Read ↗

Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.Semantic proximity Read ↗

[CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.Semantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.Semantic proximity Read ↗

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation PatientsSemantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infectionsSemantic proximity Read ↗

Inflammation is the main risk factor of voriconazole overdose in hematological patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.